Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance, Safety, and Timing of Postdose Imaging of ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Solid Tumors Undergoing Routine Surgery

Trial Profile

A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance, Safety, and Timing of Postdose Imaging of ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Solid Tumors Undergoing Routine Surgery

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jan 2019

At a glance

  • Drugs ONM 100 (Primary)
  • Indications Bladder cancer; Breast cancer; Colorectal cancer; Head and neck cancer; Ovarian cancer; Prostate cancer; Squamous cell cancer
  • Focus Adverse reactions; Diagnostic use
  • Sponsors OncoNano Medicine
  • Most Recent Events

    • 04 Jan 2019 According to an OncoNano Medicine media release, the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for ONM-100.
    • 17 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top